The iconic rise of Sildenafil presented a significant opportunity for shareholders , but its period has expired , creating a intricate landscape. Off-brand versions have flooded the space , eroding profits and putting a strain on profit yields. While leading pharmaceutical companies continue a presence in this field , the outlook seems ambiguous by